Vienna, Austria

Zehra Visram

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 8.4

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018-2022

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Zehra Visram: Innovator in Antibody Development

Introduction

Zehra Visram is a prominent inventor based in Vienna, Austria, known for her significant contributions to the field of antibody research. With a total of two patents to her name, she has made strides in developing innovative solutions for medical diagnostics and treatments.

Latest Patents

Her latest patents include groundbreaking work on antibodies targeting a galactan-based O-antigen of Klebsiella pneumoniae. This invention provides an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide O-antigen structure. The invention also details a pharmaceutical or diagnostic preparation that comprises this antibody, along with a method for producing it. Additionally, she has developed a cross-neutralizing antibody that includes at least one polyspecific binding site that binds to alpha-toxin and bi-component toxins, which has significant medical and diagnostic applications.

Career Highlights

Zehra has worked with notable companies such as Arsanis Biosciences GmbH and X4 Pharmaceuticals GmbH, where she has applied her expertise in antibody development. Her work has contributed to advancements in therapeutic and diagnostic methods in the biomedical field.

Collaborations

Throughout her career, Zehra has collaborated with esteemed colleagues, including Eszter Nagy and Gábor Nagy, enhancing her research and development efforts.

Conclusion

Zehra Visram's innovative work in antibody research exemplifies her commitment to advancing medical science. Her patents and collaborations reflect her significant impact on the field, paving the way for future developments in diagnostics and therapeutics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…